Sometimes Less Is More: Messier Nanoparticles May Actually Deliver Drugs More Effectively than Tightly Packed Ones

Why It Matters

The discovery could reshape RNA‑based therapeutics by prioritizing internal disorder over maximal loading, boosting efficacy for vaccines, cancer treatments, and genetic medicines. It also provides a scalable screening tool to accelerate formulation optimization.

Key Takeaways

• Disordered LNPs release cargo more efficiently
• Single‑particle analysis reveals two LNP subpopulations
• Organized LNPs trap RNA, reducing therapeutic effect
• High‑throughput tool screens millions of nanoparticles
• Design shift favors internal disorder over maximal loading

Pulse Analysis

Lipid nanoparticles have become the workhorse of modern biopharma, most famously delivering mRNA COVID‑19 vaccines to billions worldwide. Yet, despite their success, only a fraction—typically 1 % to 5 %—of the encapsulated RNA actually reaches the cytoplasm, limiting the potency of next‑generation therapies. This inefficiency stems from the assumption that tighter packing equals better performance, a notion that has guided formulation strategies for years. By re‑examining the fundamental physics of LNP‑cell interactions, researchers are uncovering hidden variables that could unlock higher delivery rates.

The Copenhagen team introduced a high‑throughput platform capable of measuring the size and cargo load of individual nanoparticles at scale, processing roughly one million particles per run. Their data revealed two clear subpopulations: organized particles with neatly layered interiors, and amorphous particles where the RNA and lipids are more loosely arranged. The latter’s internal charge separation allows positive lipids to repel each other under the acidic endosomal environment, causing the particle to disintegrate and release its payload. In contrast, tightly bound organized particles retain their structure, sequestering the RNA and diminishing therapeutic impact. This mechanistic insight overturns the long‑standing belief that maximal loading and structural order are optimal.

For drug developers, the implication is profound: formulation pipelines may need to pivot from maximizing payload density to engineering controlled disorder that promotes release. The new single‑particle screening tool offers a rapid, data‑driven way to evaluate thousands of candidate formulations, potentially shortening development timelines for oncology, rare‑disease, and vaccine pipelines. As the industry moves toward more sophisticated RNA therapeutics, embracing this paradigm shift could translate into higher efficacy, lower doses, and reduced manufacturing costs, ultimately accelerating patient access to cutting‑edge treatments.